Fully human protein

Low immunogenicity

Does not bind compliment and is not associated with compliment mediated cell lysis.

Dosing schedule maintains stable serum concentrations, coadministration with methotrexate does not modify etanercept pharmacokinetics

No pharmacokinetic interaction with methotrexate

Lower the risk of TB

Lower the treatment discontinuation rate

Longest drug survival times

Lowers the risk of infections

Safe and well tolerated